What is the first‑line inhaled therapy and dosing for an acute asthma exacerbation?

First-Line Inhaled Therapy for Acute Asthma Exacerbation

Administer albuterol 2.5–5 mg via nebulizer (or 4–8 puffs via metered-dose inhaler with spacer) every 20 minutes for three consecutive doses during the first hour, combined with immediate systemic corticosteroids (prednisone 40–60 mg orally for adults). 1, 2

Initial Treatment Protocol (First Hour)

Bronchodilator Dosing

• Adults: Give albuterol 2.5–5 mg via oxygen-driven nebulizer OR 4–8 puffs (360–720 mcg) via MDI with spacer every 20 minutes for three doses (at 0,20, and 40 minutes). 1, 2, 3
• Children ≥2 years: Administer 0.15 mg/kg albuterol (minimum 2.5 mg) every 20 minutes for three doses. 1
• Children <15 kg: Use half-dose (2.5 mg) for each nebulization. 1
• Each standard albuterol MDI puff delivers 90 mcg; therefore 4–8 puffs provide 360–720 mcg total dose. 1

Delivery Method Selection

• MDI with spacer is equally effective as nebulizer for mild-to-moderate exacerbations when proper technique is used and coaching provided. 1, 2
• Nebulized therapy is preferred for severe exacerbations (peak expiratory flow <50% predicted, inability to speak full sentences, respiratory rate >25/min) because it provides more reliable drug delivery when airways are severely constricted. 1, 2
• Dilute each nebulized dose in at least 3 mL normal saline and use oxygen as the driving gas at 6–8 L/min whenever feasible. 1

Concurrent Systemic Corticosteroids

• Give prednisone 40–60 mg orally immediately—do not delay while "trying bronchodilators first." 1, 2
• Oral administration is as effective as intravenous and is preferred unless the patient cannot tolerate oral intake. 1, 2
• For children, give prednisolone 1–2 mg/kg/day (maximum 60 mg/day). 1, 2
• Clinical benefits require 6–12 hours minimum to manifest, making early administration critical. 1

Reassessment After Initial Three Doses (15–30 Minutes Post-Treatment)

• Measure peak expiratory flow (PEF) before treatment and again 15–30 minutes after the first bronchodilator dose to objectively gauge severity and response. 1, 2
• Response to treatment is a better predictor of hospitalization need than initial severity. 1, 2

Response-Based Management

Good Response (PEF >75% predicted):

• Continue usual maintenance therapy with modest step-up. 1
• Arrange follow-up within 48 hours. 1

Incomplete Response (PEF 50–75% predicted):

• Continue albuterol 2.5–5 mg every 1–4 hours as needed. 1, 2, 3
• Maintain systemic corticosteroids. 1
• Consider hospital admission if severe features persist. 1

Poor Response (PEF <50% predicted or persistent severe symptoms):

• Increase nebulizer frequency to every 15–30 minutes. 1
• Add ipratropium bromide 0.5 mg to each albuterol dose. 1, 2
• Arrange immediate hospital admission. 1, 2

Adjunctive Ipratropium Bromide

• Add ipratropium bromide 0.5 mg (or 8 puffs via MDI) to albuterol for all moderate-to-severe exacerbations. 1, 2
• Administer every 20 minutes for three doses, then every 4–6 hours as needed. 1, 2
• The combination significantly reduces hospitalization rates, particularly in severe airflow obstruction. 1, 2

Severe or Life-Threatening Exacerbations

Continuous Nebulization

• For patients not responding to intermittent dosing, use continuous albuterol nebulization at 10–15 mg/hour for adults or 0.5 mg/kg/hour for children. 1

Intravenous Magnesium Sulfate

• Give magnesium sulfate 2 g IV over 20 minutes for life-threatening features or severe exacerbations remaining after 1 hour of intensive treatment. 1, 2
• For children, dose is 25–75 mg/kg (maximum 2 g) IV over 20 minutes. 1

Life-Threatening Indicators Requiring ICU Consideration

• PEF <33% predicted. 1, 2
• Silent chest, cyanosis, or feeble respiratory effort. 1, 2
• Altered mental status (confusion, drowsiness, exhaustion). 1, 2
• Normal or elevated PaCO₂ ≥42 mmHg in a breathless patient. 1, 2
• Inability to speak full sentences. 1, 2

Supplemental Oxygen

• Administer oxygen via nasal cannula or face mask to maintain SpO₂ >90% (target >95% in pregnant patients or those with cardiac disease). 1, 2
• Continue oxygen saturation monitoring until clear response to bronchodilator therapy occurs. 2

Critical Pitfalls to Avoid

• Never delay corticosteroid administration while "trying bronchodilators first"—both must be given concurrently. 1
• Never administer sedatives to patients with acute asthma; they are absolutely contraindicated and potentially fatal. 1, 2
• Do not rely solely on subjective assessment—objective PEF or FEV₁ measurement is essential to prevent underestimating severity. 1, 2
• Do not substitute MDI for nebulizer in severe exacerbations without evidence of adequate response. 1
• Using only 2 puffs of albuterol MDI is inadequate for acute exacerbations; 4–8 puffs are required to approximate nebulizer dosing. 1

Monitoring Parameters

• Watch for tachycardia, tremor, and hypokalemia, especially with frequent or high-dose albuterol administration. 1
• Most patients tolerate albuterol well even with repeated dosing. 1, 3
• Inhaled albuterol produces fewer cardiovascular effects than oral or parenteral routes. 3

Discharge Criteria

• PEF ≥70% of predicted or personal best. 1, 2
• Minimal or absent symptoms. 1, 2
• Patient stable for 30–60 minutes after last bronchodilator dose. 1, 2
• Oxygen saturation stable on room air. 2
• Continue oral corticosteroids for 5–10 days (no taper needed for courses <10 days). 1, 2